1. Structural basis for the EBA-175 erythrocyte invasion pathway of themalaria parasite Plasmodium falciparum Tolia NH, Enemark EJ, Sim KL, Joshua-Tor L Cell 122: 183-193, 2005 Structural basis for Duffy recognition by the malaria parasite Duffy- binding–like domain Singh SK, Hora R, Belrhali H, Chitnis CE, Sharma A Nature 439: 741-744, 2005 Microbiology Department Journal Club

2. Background Plasmodium causes Malaria which affects more than 500 million people and kills about two million annually. P. falciparum is the most prevalent; P. vivax less so; P. knowlesi is the simian counterpart. Infection is caused by sporozoites entering into the host bloodstream after a female Anopheles mosquito bite and infecting hepatocytes; the hepatocytes rupture and release thousands of merozoites each of which can invade an erythrocyte, thus initiating the asexual erythrocytic stage of the parasite’s life cycle. All pathological and clinical manifestations of the disease are caused by this critical invasion step.

3. Background, continued… Binding to the host endothelium is accomplished through the function of a common adhesion molecule found in two families of parasite ligands. EBL (erythrocyte binding ligand) family of erythrocyte invasion ligands and the var/PfEMP1 (P. falciparum erythrocyte membrane protein 1) family of cytoadherence ligands This adhesive domain, called the Duffy-binding like (DBL) domain was first described as part of the Duffy Binding Protein (DBP), an important invasion ligand of both P. vivax and P. knowlesi for erythrocytes. DBL domains contribute to both invasion and cytoadherence and are one of the most versatile and polymorphic adhesive molecules. X-ray crystallography structures of the DBL domains from two well- studied EBL ligands, the P. knowlesi DBP (PkDBP) and the P. falciparum EBA-175, have been published.

4. EBP, EBA, PfEMP, … Nature 439: 741-744, 2005

5. EBL, DBL, DBP, PfEMP, … Cell 122: 183-193, 2005 erythrocyte binding domain (critical)

6. PkDBP alignments Nature 439: 741-744, 2005

7. EBA-175 alignments Cell 122: 183-193, 2005

8. PkDBP structure (3 Å) 11 alpha helices, unique fold, three subdomains Nature 439: 741-744, 2005

9. EBA-175 structure (2.3 Å) Cell 122: 183-193, 2005

10. Binding DBL domains bind several substrates and have different binding sites, sometimes involving dimerisation. EBA-175 and PkDBP bind different receptors on the erythrocyte surface. PkDBL (and PvDBL) bind the host DARC (Duffy antigen receptor for chemokines); mutagenesis data available. EBA-175, BAEBL, and JSEBL all can bind sialic acid residues, but each recognises different erythrocyte sialoglycoproteins; receptor for EBA- 175 is human RBC receptor glycophorin A. Redundant pathways means that EBA-175 is not essential. X-ray structure of EBA-175 was solved with sialic acid derivative, alpha-2,3,sialyllactoase to identify the glycan binding site; additional mutagenesis experiments were performed.

11. PkDBL binding Nature 439: 741-744, 2005

12. PvDBL binding Nature 439: 741-744, 2005 polymorphic residues in field isolates; immune system evasion binding site “just-in-time” release and binding to receptor

13. PkDBL binding SD1 SD2 DARC binding site antigenic site antigenic site

14. EBA-175 binding Cell 122: 183-193, 2005

15. Model for EBA-175 region 2 binding to glycophorin A Cell 122: 183-193, 2005

16. Superimposed DBLs (within 2 Å of each other) DARC binding site glycan binding sites

17. A treasure of insights

18. DARC binding site glycan binding site

19. Conclusions – insights from x-ray structures Different sites target different substrates and receptors in different DBL domains Interplay between sequence conservation and variation to evade immune evasion For PvDBL, target the DBL-DARC interaction for therapeutics (conserved) For EBA-175, target the glycan binding sites; distrupt dimersation and/or DBL domain interactions